ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Editing

Regeneron expands CRISPR partnership with Intellia

by Ryan Cross
June 5, 2020 | APPEARED IN VOLUME 98, ISSUE 22

 

Regeneron has expanded the collaboration it began in 2016 with the CRISPR gene-editing company Intellia Therapeutics. The two firms will codevelop an in vivo therapy for hemophilia A and B that uses CRISPR to insert a blood clotting–factor gene into liver cells. Regeneron will pay Intellia $70 million up front and purchase $30 million of the company’s stock. Regeneron also has the rights to develop up to 15 more in vivo CRISPR therapies with Intellia and up to 10 gene-edited cell therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment